NASDAQ: IPHA
Innate Pharma Sa Stock Ownership - Who owns Innate Pharma Sa?

Insider buying vs selling

Have Innate Pharma Sa insiders been buying or selling?

No trades
There has been no insiders buying vs selling in the past 12 months.

Be the first to know when IPHA insiders and whales buy or sell their stock.

IPHA Shareholders

What type of owners hold Innate Pharma Sa stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Morgan Stanley0.06%51,224$115.25kInstitution
Citadel Advisors LLC0.03%26,617$59.89kInstitution
Millennium Management LLC0.01%11,661$26.24kInstitution
Ubs Group Ag0.01%5,957$13.40kInstitution
Gamma Investing LLC0.00%3,456$7.78kInstitution
Rhumbline Advisers0.00%470$1.06kInstitution
Barclays PLC0.00%307$690.75Institution
Optiver Holding Bv0.00%101$227.25Institution
Principal Securities Inc0.00%45$101.25Institution
Concourse Financial Group Securities Inc0.00%0$0.00Institution

1 of 1

IPHA vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
IPHA0.12%0.00%
MNPR13.57%86.43%Net SellingNet Selling
MDWD40.84%0.00%
EPRX5.48%0.00%
KRRO24.31%75.69%Net Buying

Innate Pharma Sa Stock Ownership FAQ

Who owns Innate Pharma Sa?

Innate Pharma Sa (NASDAQ: IPHA) is owned by 0.12% institutional shareholders, 0.00% Innate Pharma Sa insiders, and 99.88% retail investors. Morgan Stanley is the largest individual Innate Pharma Sa shareholder, owning 51,224.00 shares representing 0.06% of the company. Morgan Stanley's Innate Pharma Sa shares are currently valued at $114.74k.

If you're new to stock investing, here's how to buy Innate Pharma Sa stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.